XLONAPTA
Market cap9mUSD
Dec 24, Last price
0.37GBP
1D
0.00%
1Q
68.18%
IPO
-99.74%
Name
Aptamer Group PLC
Chart & Performance
P/E
—
P/S
855.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
43.20%
Rev. gr., 5y
-2.71%
Revenues
860k
-50.91%
Net income
-3m
L-62.25%
CFO
-2m
L-43.80%
Earnings
Mar 26, 2025
Profile
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom and internationally. The company's binders engineered to address issues which founds with molecules, such as antibodies; and offers solutions to bioprocessing, diagnostic, and pharmaceutical scientists. It serves pharma companies, diagnostic development companies, and research institutes. The company was incorporated in 2014 and is based in York, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑03 | 2019‑03 | |
| Income | ||||||
Revenues | 860 -50.91% | 1,752 -56.59% | 4,036 215.31% | |||
Cost of revenue | 3,777 | 6,901 | 6,551 | |||
Unusual Expense (Income) | ||||||
NOPBT | (2,917) | (5,149) | (2,515) | |||
NOPBT Margin | ||||||
Operating Taxes | (183) | (462) | (545) | |||
Tax Rate | ||||||
NOPAT | (2,734) | (4,687) | (1,970) | |||
Net income | (2,958) -62.25% | (7,836) 274.39% | (2,093) 13.16% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,911 | 5 | 9,582 | |||
BB yield | ||||||
| Debt | ||||||
Debt current | 253 | 50 | 248 | |||
Long-term debt | 1,334 | 1,028 | 2,329 | |||
Deferred revenue | 3 | 7 | ||||
Other long-term liabilities | 35 | 745 | 35 | |||
Net debt | 344 | 471 | (4,493) | |||
| Cash flow | ||||||
Cash from operating activities | (2,284) | (4,064) | (2,375) | |||
CAPEX | (14) | (2,028) | (418) | |||
Cash from investing activities | (122) | (2,028) | (418) | |||
Cash from financing activities | 3,042 | (365) | 9,115 | |||
FCF | (2,628) | (3,421) | (3,966) | |||
| Balance | ||||||
Cash | 870 | 234 | 6,691 | |||
Long term investments | 373 | 373 | 379 | |||
Excess cash | 1,200 | 519 | 6,868 | |||
Stockholders' equity | (11,785) | (9,459) | (1,707) | |||
Invested Capital | 13,527 | 10,499 | 10,996 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 415,108 | 69,055 | 69,023 | |||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (2,672) | (4,349) | (2,061) | |||
EV/EBITDA | ||||||
Interest | 81 | 134 | 46 | |||
Interest/NOPBT | ||||||